publication date: Jun. 2, 2016

NCI CTEP-Approved Trials for the Month of May

 

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase I

9899: A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients with Advanced Solid Tumors. Dana-Farber – Harvard Cancer Center LAO; Do, Khanh Tu. (617) 632-6992

 

9930: A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL). University Health Network Princess Margaret Cancer Center LAO; Chavez, Julio C. (813) 745-1867

 

Phase II

9875: Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL. Dana-Farber – Harvard Cancer Center LAO; Jacobson, Caron Alyce. (617) 582-7591

 

9881: A Phase 2 Study of Cediranib in Combination … Continue reading CCL May – NCI CTEP-Approved Trials for the Month of May

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.